[go: up one dir, main page]

AR073069A1 - Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas. - Google Patents

Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas.

Info

Publication number
AR073069A1
AR073069A1 ARP090103159A ARP090103159A AR073069A1 AR 073069 A1 AR073069 A1 AR 073069A1 AR P090103159 A ARP090103159 A AR P090103159A AR P090103159 A ARP090103159 A AR P090103159A AR 073069 A1 AR073069 A1 AR 073069A1
Authority
AR
Argentina
Prior art keywords
mesenquimatic
compositions
purified
mother
purify
Prior art date
Application number
ARP090103159A
Other languages
English (en)
Inventor
Robert E Newman
Alla Danikovich
Samson Tom
Christopher Ton
Zhanling Wang
Randall Young
Original Assignee
Osiris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41669330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073069(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osiris Therapeutics Inc filed Critical Osiris Therapeutics Inc
Publication of AR073069A1 publication Critical patent/AR073069A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Composiciones farmacéuticas de una o más células madre mesenquimáticas purificadas y métodos de elaboracion utilizando filtracion por centrifugacion. Se divulgan asimismo los límites umbral de administracion intravenosa de composiciones farmacéuticas de células madre mesenquimáticas que comprenden productos residuales de origen animal. Reivindicacion 1: Una composicion farmacéuticamente aceptable que comprende células madre mesenquimáticas purificadas, donde la composicion comprende uno o más agregados de células madre mesenquimáticas y donde el D90 de dichos agregados es menor que aproximadamente 150 mm.
ARP090103159A 2008-08-14 2009-08-18 Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas. AR073069A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8889808P 2008-08-14 2008-08-14

Publications (1)

Publication Number Publication Date
AR073069A1 true AR073069A1 (es) 2010-10-13

Family

ID=41669330

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090103159A AR073069A1 (es) 2008-08-14 2009-08-18 Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas.
ARP200101271A AR123811A2 (es) 2008-08-14 2020-05-05 Composiciones de células madre mesenquimáticas purificadas y métodos relacionados

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200101271A AR123811A2 (es) 2008-08-14 2020-05-05 Composiciones de células madre mesenquimáticas purificadas y métodos relacionados

Country Status (14)

Country Link
US (6) US8637004B2 (es)
EP (3) EP2318519B1 (es)
JP (7) JP6025329B2 (es)
AR (2) AR073069A1 (es)
AU (1) AU2009281809B2 (es)
BR (1) BRPI0917993B8 (es)
CA (1) CA2733985C (es)
DK (1) DK2318519T3 (es)
ES (1) ES2608974T3 (es)
IL (1) IL211214A0 (es)
MX (2) MX2011001730A (es)
NZ (2) NZ591146A (es)
WO (1) WO2010019886A1 (es)
ZA (1) ZA201101858B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530543A (ja) 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
BRPI0706529A2 (pt) 2006-01-13 2011-03-29 Osiris Therapeutics Inc células-tronco mesenquimais que expressam receptores de tnf-alfa
NZ591146A (en) 2008-08-14 2012-10-26 Osiris Therapeutics Inc Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
KR20110050521A (ko) 2008-08-20 2011-05-13 안트로제네시스 코포레이션 개선된 세포 조성물 및 그의 제조 방법
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
EP4663241A2 (en) 2010-10-08 2025-12-17 Mesoblast International Sàrl Enhanced msc preparations
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
ITGE20120034A1 (it) * 2012-03-28 2013-09-29 Carlo Tremolada Preparato e metodo per la produzione di un preparato comprendente cellule staminali mesenchimali
JP2013252126A (ja) * 2012-05-08 2013-12-19 Otsuka Pharmaceut Factory Inc デキストラン含有肺塞栓形成予防用哺乳動物細胞懸濁液
WO2014150784A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10449283B2 (en) * 2016-04-29 2019-10-22 Fenwal, Inc. System and method for selecting and culturing cells
EP3238759B1 (en) 2016-04-29 2019-07-17 Fenwal, Inc. System and method for processing, incubating and/or selecting biological cells
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10274495B2 (en) 2016-12-21 2019-04-30 Fenwal, Inc. System and method for separating cells incorporating magnetic separation
CN110612344B (zh) 2017-03-31 2023-09-12 泰尔茂比司特公司 细胞扩增
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN112004923A (zh) 2017-11-22 2020-11-27 迈索布拉斯特国际有限公司 细胞组合物及治疗方法
EP3781597A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
EP3847241A1 (en) * 2018-10-26 2021-07-14 Stemselect Method and apparatus for mesenchymal stem cells isolation and purification
US11618776B2 (en) 2018-12-20 2023-04-04 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains
WO2020231968A1 (en) * 2019-05-15 2020-11-19 Stemcyte Inc. High concentration cell packaging and shipping
WO2021144995A1 (ja) * 2020-01-16 2021-07-22 ＰｕＲＥＣ株式会社 高純度間葉系幹細胞
WO2021226373A2 (en) 2020-05-08 2021-11-11 Gallant Pet, Inc. Uterine-derived regenerative cell compositions and uses thereof
WO2022204315A1 (en) 2021-03-23 2022-09-29 Terumo Bct, Inc. Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN115478046A (zh) * 2022-09-30 2022-12-16 浙江泉生生物科技有限公司 一种降低血清培养体系中细胞制剂bsa残留量的方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034135A (en) 1982-12-13 1991-07-23 William F. McLaughlin Blood fractionation system and method
US4803075A (en) * 1986-06-25 1989-02-07 Collagen Corporation Injectable implant composition having improved intrudability
EP0277994B1 (en) 1986-08-11 1991-09-04 BAXTER INTERNATIONAL INC. (a Delaware corporation) Blood cell washing systems and methods
US5536475A (en) 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5226914A (en) 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5234608A (en) * 1990-12-11 1993-08-10 Baxter International Inc. Systems and methods for processing cellular rich suspensions
WO1995033421A1 (en) * 1994-06-06 1995-12-14 Case Western Reserve University Biomatrix for tissue regeneration
US5707996A (en) * 1995-11-06 1998-01-13 Macleod Pharmaceuticals, Inc. Pharmaceutical solution and methods for preparation thereof
ATE439849T1 (de) * 1996-04-19 2009-09-15 Osiris Therapeutics Inc Die wiederherstellung und verstärkung von knochen mittels mesenchymalen stammzellen
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
WO1999003973A1 (en) * 1997-07-14 1999-01-28 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6251295B1 (en) 1998-01-08 2001-06-26 Nexell Therapeutics Inc. Method for recirculation washing of blood cells
ATE316795T1 (de) 1998-03-18 2006-02-15 Osiris Therapeutics Inc Mesenchymale stammzellen für die prävention und behandlung von immunantworten bei transplantationen
WO1999061588A1 (en) * 1998-05-22 1999-12-02 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
FR2787463B1 (fr) 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
JP2002325572A (ja) * 2000-12-25 2002-11-12 Univ Osaka 外来物質の導入方法
US20030054331A1 (en) * 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
US9597395B2 (en) * 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
US20050095228A1 (en) * 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US20050048036A1 (en) * 2001-12-07 2005-03-03 Hedrick Marc H. Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues
US20050048035A1 (en) * 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US7514075B2 (en) * 2001-12-07 2009-04-07 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating adipose derived stem cells from tissue
US8404229B2 (en) * 2001-12-07 2013-03-26 Cytori Therapeutics, Inc. Methods of using adipose derived stem cells to treat acute tubular necrosis
US7585670B2 (en) * 2001-12-07 2009-09-08 Cytori Therapeutics, Inc. Automated methods for isolating and using clinically safe adipose derived regenerative cells
JP4653952B2 (ja) * 2001-12-07 2011-03-16 サイトリ セラピューティクス インコーポレイテッド 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法
US20050008626A1 (en) * 2001-12-07 2005-01-13 Fraser John K. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
ITTO20020311A1 (it) * 2002-04-10 2003-10-10 Medestea Int Spa Procedimento per la preparazione di cellule staminali da tessuto muscolare e tessuto adiposo umano e cellule staminali ottenibili mediante t
ZA200404101B (en) 2003-05-26 2005-03-07 Reliance Life Sciences Pvt Ltd In vitro culture of Mesenchymal Stem Cells (MSC) and a process for the preparation thereof for therapeutic use.
EP2380970B1 (en) 2003-06-25 2017-12-20 Cytori Therapeutics, Inc. Systems and methods for separating and concentrating regenerative cells from tissue
JP2007530543A (ja) 2004-03-22 2007-11-01 オシリス セラピューティクス，インコーポレイテッド 間葉幹細胞及びその使用法
JP3828905B2 (ja) * 2004-08-05 2006-10-04 株式会社Ｒ＆Ｄセルサイエンス・オプショナルメディコ 局所麻酔薬を含有する細胞凝集抑制剤
US8512724B2 (en) * 2005-06-10 2013-08-20 The Board Of Regents Of The University Of Texas System Antiseptic compositions
AU2006292203A1 (en) 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
US7888119B2 (en) * 2005-10-14 2011-02-15 University Of Central Florida Research Foundation, Inc. Tissue substitutes comprising stem cells and reduced ceria
US20070253931A1 (en) * 2006-01-12 2007-11-01 Osiris Therapeutics, Inc. Use of mesenchymal stem cells for treating genetic diseases and disorders
CA2641022A1 (en) 2006-01-30 2007-08-09 University Of Virginia Patent Foundation Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof
EP2021035B1 (en) 2006-05-19 2020-08-05 Versitech Limited Cell-matrix microspheres, methods for preparation and applications
KR20090043559A (ko) 2006-08-15 2009-05-06 에이전시 포 사이언스, 테크놀로지 앤드 리서치 중간엽 줄기세포 조절배지
ES2362150T3 (es) 2006-11-03 2011-06-29 Aastrom Biosciences, Inc. Poblaciones celulares mixtas para la reparación de tejidos y técnica de separación para el procesamiento celular.
JP2008139106A (ja) * 2006-11-30 2008-06-19 Sysmex Corp 骨髄穿刺液収容具及び骨髄穿刺液濾過方法
WO2008073331A2 (en) 2006-12-07 2008-06-19 Teva Pharmaceutical Industries Ltd. Method of generation and expansion of tissue-progenitor cells and mature tissue cells from intact bone marrow or intact umbilical cord tissue
CN101210232B (zh) * 2006-12-28 2012-07-18 天津昂赛细胞基因工程有限公司 一种间充质干细胞保存液
WO2009031606A1 (ja) 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
EP2210608B1 (en) 2007-11-02 2016-08-31 JCR Pharmaceuticals CO., LTD. Pharmaceutical composition containing human mesenchymal stem cell
NZ591146A (en) 2008-08-14 2012-10-26 Osiris Therapeutics Inc Composition comprising mesenchymal stem cell aggregates wherein the D90 of said aggregates is less than 150 micomills
US8048976B2 (en) 2008-09-04 2011-11-01 Amyris, Inc. Polyfarnesenes
US10476476B2 (en) 2016-12-15 2019-11-12 Murata Manufacturing Co., Ltd. MEMS resonator with suppressed spurious modes

Also Published As

Publication number Publication date
IL211214A0 (en) 2011-04-28
US20200197444A1 (en) 2020-06-25
JP2017081972A (ja) 2017-05-18
JP6025329B2 (ja) 2016-11-16
ES2608974T3 (es) 2017-04-17
JP2015071610A (ja) 2015-04-16
JP2020120671A (ja) 2020-08-13
DK2318519T3 (en) 2017-01-16
JP2018109052A (ja) 2018-07-12
JP2012500214A (ja) 2012-01-05
BRPI0917993B1 (pt) 2020-12-29
AU2009281809B2 (en) 2015-09-17
BRPI0917993B8 (pt) 2021-05-25
NZ602248A (en) 2014-03-28
JP7580202B2 (ja) 2024-11-11
US20180008642A1 (en) 2018-01-11
BRPI0917993A2 (pt) 2017-10-10
MX2011001730A (es) 2011-03-24
AR123811A2 (es) 2023-01-18
MX362512B (es) 2019-01-22
EP2318519A1 (en) 2011-05-11
NZ591146A (en) 2012-10-26
US20250312379A1 (en) 2025-10-09
US20100068191A1 (en) 2010-03-18
JP2025122125A (ja) 2025-08-20
US8637004B2 (en) 2014-01-28
CA2733985C (en) 2016-07-12
EP4477742A2 (en) 2024-12-18
JP2023052211A (ja) 2023-04-11
US20140105872A1 (en) 2014-04-17
EP3124601A1 (en) 2017-02-01
CA2733985A1 (en) 2010-02-18
EP4477742A3 (en) 2025-02-26
WO2010019886A1 (en) 2010-02-18
ZA201101858B (en) 2011-11-30
US20230089901A1 (en) 2023-03-23
AU2009281809A1 (en) 2010-02-18
EP2318519B1 (en) 2016-10-05
EP2318519A4 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
AR073069A1 (es) Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas.
AR089578A1 (es) Composiciones, metodos para tratar el virus de la hepatitis c y proceso de preparacion
UY31164A1 (es) Nuevos derivados de bencimidazol, composiciones farmacéuticas conteniéndolos y aplicaciones
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
PE20140978A1 (es) Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla
UY33044A (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
ECSP088871A (es) Derivados de triazolopirazina
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
BR112013000750A2 (pt) 1-hidroxiimino-3-fenil-propanos
CR20190331A (es) UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549)
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP11011560A (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
BRPI0924617A8 (pt) Compostos heterociclicos de fenoximetila
GT200900217A (es) Nuevos compuestos triciclicos, un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
BR112013018688A2 (pt) processo para a produção de composição polimérica de proantocianidina

Legal Events

Date Code Title Description
FC Refusal